COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: imm...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Fundació Sant Joan de Déu |
| Repositorio: | r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| OAI Identifier: | oai:fsjd.fundanetsuite.com:p21368 |
| Acceso en línea: | https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21368 |
| Access Level: | acceso abierto |
| Palabra clave: | allergen allergy biologicals Covid-19 immunotherapy mRNA vaccines |
| id |
ES_76962f1202deafd83201dc30c87e2bde |
|---|---|
| oai_identifier_str |
oai:fsjd.fundanetsuite.com:p21368 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendationsJutel, MTorres, MJPalomares, OAkdis, CAEiwegger, TUntersmayr, EBarber, DZemelka-Wiacek, MKosowska, APalmer, EVieths, SMahler, VCanonica, WGNadeau, KShamji, MHAgache, IAkdis, MKhaitov, MAlvarez-Perea, AAlvaro-Lozano, MAtanaskovic-Markovic, MBacker, VBarbaud, ABavbek, Sde Blay, FBonini, MBonini, Svan Boven, JFMBrockow, KCazzola, MChatzipetrou, AChivato, TCianferoni, ACorren, JCristoph-Caubet, JDunn-Galvin, AEbisawa, MFirinu, DGawlik, RGelincik, Adel Giacco, SMortz, CGHoffmann, HJHoffmann-Sommergruber, KKlimek, LKnol, ELauerma, Ade Llano, LPMatucci, AMeyer, RMoreira, AMorita, HPatil, SUPfaar, OPopescu, FDdel Pozo, VPrice, OJvan Ree, RFernandez-Rivas, MRogala, BRomano, ASantos, ASediva, ASkypala, ISmolinska, SSokolowska, MSturm, GVultaggio, AWalusiak-Skorupa, JWorm, MallergenallergybiologicalsCovid-19immunotherapymRNA vaccinesImmune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.WILEY2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21368ALLERGYISSN: 01054538ISSNe: 13989995reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p213682026-05-27T12:37:41Z |
| dc.title.none.fl_str_mv |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| title |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| spellingShingle |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations Jutel, M allergen allergy biologicals Covid-19 immunotherapy mRNA vaccines |
| title_short |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| title_full |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| title_fullStr |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| title_full_unstemmed |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| title_sort |
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations |
| dc.creator.none.fl_str_mv |
Jutel, M Torres, MJ Palomares, O Akdis, CA Eiwegger, T Untersmayr, E Barber, D Zemelka-Wiacek, M Kosowska, A Palmer, E Vieths, S Mahler, V Canonica, WG Nadeau, K Shamji, MH Agache, I Akdis, M Khaitov, M Alvarez-Perea, A Alvaro-Lozano, M Atanaskovic-Markovic, M Backer, V Barbaud, A Bavbek, S de Blay, F Bonini, M Bonini, S van Boven, JFM Brockow, K Cazzola, M Chatzipetrou, A Chivato, T Cianferoni, A Corren, J Cristoph-Caubet, J Dunn-Galvin, A Ebisawa, M Firinu, D Gawlik, R Gelincik, A del Giacco, S Mortz, CG Hoffmann, HJ Hoffmann-Sommergruber, K Klimek, L Knol, E Lauerma, A de Llano, LP Matucci, A Meyer, R Moreira, A Morita, H Patil, SU Pfaar, O Popescu, FD del Pozo, V Price, OJ van Ree, R Fernandez-Rivas, M Rogala, B Romano, A Santos, A Sediva, A Skypala, I Smolinska, S Sokolowska, M Sturm, G Vultaggio, A Walusiak-Skorupa, J Worm, M |
| author |
Jutel, M |
| author_facet |
Jutel, M Torres, MJ Palomares, O Akdis, CA Eiwegger, T Untersmayr, E Barber, D Zemelka-Wiacek, M Kosowska, A Palmer, E Vieths, S Mahler, V Canonica, WG Nadeau, K Shamji, MH Agache, I Akdis, M Khaitov, M Alvarez-Perea, A Alvaro-Lozano, M Atanaskovic-Markovic, M Backer, V Barbaud, A Bavbek, S de Blay, F Bonini, M Bonini, S van Boven, JFM Brockow, K Cazzola, M Chatzipetrou, A Chivato, T Cianferoni, A Corren, J Cristoph-Caubet, J Dunn-Galvin, A Ebisawa, M Firinu, D Gawlik, R Gelincik, A del Giacco, S Mortz, CG Hoffmann, HJ Hoffmann-Sommergruber, K Klimek, L Knol, E Lauerma, A de Llano, LP Matucci, A Meyer, R Moreira, A Morita, H Patil, SU Pfaar, O Popescu, FD del Pozo, V Price, OJ van Ree, R Fernandez-Rivas, M Rogala, B Romano, A Santos, A Sediva, A Skypala, I Smolinska, S Sokolowska, M Sturm, G Vultaggio, A Walusiak-Skorupa, J Worm, M |
| author_role |
author |
| author2 |
Torres, MJ Palomares, O Akdis, CA Eiwegger, T Untersmayr, E Barber, D Zemelka-Wiacek, M Kosowska, A Palmer, E Vieths, S Mahler, V Canonica, WG Nadeau, K Shamji, MH Agache, I Akdis, M Khaitov, M Alvarez-Perea, A Alvaro-Lozano, M Atanaskovic-Markovic, M Backer, V Barbaud, A Bavbek, S de Blay, F Bonini, M Bonini, S van Boven, JFM Brockow, K Cazzola, M Chatzipetrou, A Chivato, T Cianferoni, A Corren, J Cristoph-Caubet, J Dunn-Galvin, A Ebisawa, M Firinu, D Gawlik, R Gelincik, A del Giacco, S Mortz, CG Hoffmann, HJ Hoffmann-Sommergruber, K Klimek, L Knol, E Lauerma, A de Llano, LP Matucci, A Meyer, R Moreira, A Morita, H Patil, SU Pfaar, O Popescu, FD del Pozo, V Price, OJ van Ree, R Fernandez-Rivas, M Rogala, B Romano, A Santos, A Sediva, A Skypala, I Smolinska, S Sokolowska, M Sturm, G Vultaggio, A Walusiak-Skorupa, J Worm, M |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
allergen allergy biologicals Covid-19 immunotherapy mRNA vaccines |
| topic |
allergen allergy biologicals Covid-19 immunotherapy mRNA vaccines |
| description |
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21368 |
| url |
https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21368 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
WILEY |
| publisher.none.fl_str_mv |
WILEY |
| dc.source.none.fl_str_mv |
ALLERGY ISSN: 01054538 ISSNe: 13989995 reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname:Fundació Sant Joan de Déu |
| instname_str |
Fundació Sant Joan de Déu |
| reponame_str |
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| collection |
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869411061632860160 |
| score |
15,811543 |